Gilead Sciences GILD Europe — Total revenues
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's europe — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's europe — total revenues?
- Gilead Sciences (GILD) reported europe — total revenues of $1.14B in Q1 2026.
- How has Gilead Sciences's europe — total revenues changed year-over-year?
- Gilead Sciences's europe — total revenues increased by 5.5% year-over-year, from $1.08B to $1.14B.
- What is the long-term trend for Gilead Sciences's europe — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's europe — total revenues has grown at a 1.0% compound annual growth rate (CAGR), from $4.87B to $5.06B.
- What does europe — total revenues mean?
- The total amount of money earned from sales in the European market.
- How do you interpret europe — total revenues?
- An increase indicates successful product adoption, favorable pricing, or expanded market access in Europe, while a decrease may signal increased competition, patent expirations, or regulatory pricing pressures.
- How does europe — total revenues compare across companies?
- Comparable to regional revenue reporting by other multinational pharmaceutical companies, which typically track performance by major geographic segments to isolate regional economic and regulatory impacts.